Premium
Second‐trimester maternal urinary gonadotrophin peptide screening for fetal Down syndrome in Asian women
Author(s) -
Lam Yung Hang,
Tang Mary Hoi Yin,
Tang Lawrence Chang Hung,
Lee Chin Peng,
Ho Philip Kin Hoi
Publication year - 1997
Publication title -
prenatal diagnosis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.956
H-Index - 97
eISSN - 1097-0223
pISSN - 0197-3851
DOI - 10.1002/(sici)1097-0223(199712)17:12<1101::aid-pd195>3.0.co;2-s
Subject(s) - medicine , down syndrome , urinary system , confidence interval , gestation , creatinine , urine , pregnancy , population , obstetrics , fetus , gynecology , endocrinology , physiology , biology , genetics , environmental health , psychiatry
Maternal urinary gonadotrophin peptide (UGP) was recently found to be elevated in second‐trimester Down syndrome pregnancies. There is controversy about its screening efficacy. Data in the Asian population are scanty. We measured the UGP levels in 29 Down syndrome pregnancies and 297 controls and expressed them as a ratio of the urine creatinine concentration. Median UGP MOM was elevated to 3·44 (95 per cent confidence interval 1·99–5·13) in cases, compared with controls. UGP values were widely scattered in cases and controls with extensive overlap such that only 35 per cent of Down syndrome cases were expected to be detected at a 5 per cent false‐positive rate. The data of the present study and previous reports show that there is a wide variability of gestation‐specific UGP median values. UGP alone does not appear to be an effective screening marker for fetal Down syndrome. © 1997 John Wiley & Sons, Ltd.